Amphetamine News and Research

RSS

Lightlake announces final data from naloxone nasal spray Phase II study on Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today compelling final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED).

9 Aug 2012

Scientists analyze raw sewage samples to determine illicit drug use

Surveys of drug use form an important basis for the development of effective drug policies, and also for measuring the effectiveness of existing policies. For the first time in history, scientists have now made direct comparisons of illicit drug use in 19 European cities by a cooperative analysis of raw sewage samples.

27 Jul 2012

Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Raising levels of the neurotransmitter dopamine in the frontal cortex of the brain significantly decreased impulsivity in healthy adults, in a study conducted by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco.

26 Jul 2012

HIV in MSM increasing in countries of all incomes

A new Lancet Series published to coincide with the AIDS2012 meeting highlights a population where the HIV epidemic is growing in countries of all incomes: men who have sex with men (MSM). The first paper in the Series charts the epidemiology of HIV among MSM, and is by Professor Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, and colleagues.

20 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

FDA approves Actavis Mixed Amphetamine Salts ER Capsules

Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII, (hereafter referred to as Mixed Amphetamine Salts ER Capsules), in all available strengths: 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg.

25 Jun 2012

Longer looks: Battling HIV in Washington; Adderall use among U.S. high schoolers

On a recent day not far from Capitol Hill and the White House, about a dozen HIV outreach workers toting bright yellow duffle bags stuffed with condoms and prevention information stood outside of the Anacostia Metro station. ... After a couple of hours, they had handed out hundreds of packs of condoms -- and had persuaded 21 people to take an HIV test with an oral swab in a Chevy van parked nearby. "You have to know your status, man. I'd rather be safe than sorry," said Alvern Harris, 25, as he waited for his results.

15 Jun 2012

Pisgah receives USPTO Notice of Allowance for drug abuse solution

Pisgah Laboratories, Inc. received Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties."

2 Jun 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine.

26 Apr 2012

Ecstasy and speed-using grade ten students more likely to develop depression

A five year study conducted with thousands of local teenagers by University of Montreal researchers reveals that those who used speed (meth/ampthetamine) or ecstasy (MDMA) at fifteen or sixteen years of age were significantly more likely to suffer elevated depressive symptoms the following year. "Our findings are consistent with other human and animal studies that suggest long-term negative influences of synthetic drug use," said co-author Fr-d-ric N. Bri-re of the School Environment Research Group at the University of Montreal.

19 Apr 2012

Study investigates knowledge about khat among medical students in Yemen

A new study conducted by Boston University School of Medicine (BUSM) researchers shows that a majority of medical students in Yemen believe that chewing the plant khat is harmful to one's health but they would not advise their patients to quit.

8 Mar 2012

Young children more likely to be diagnosed and treated for ADHD

The youngest children in the classroom are significantly more likely to be diagnosed with attention-deficit/hyperactivity disorder (ADHD) - and prescribed medication - than their peers in the same grade, according to a study just published in CMAJ.

6 Mar 2012

Bath salts mimic effects of two powerful narcotics

The street drug commonly referred to as "bath salts" is one of a growing list of synthetic and unevenly regulated narcotics that are found across the United States and on the Internet. New research on this potent drug paints an alarming picture, revealing that bath salts pack a powerful double punch, producing combined effects similar to both methamphetamine (METH) and cocaine.

24 Feb 2012

Internet supplements - one click toward poor performance

Sports Medicine Australia, the peak organisation for professionals in sports medicine and sports science, has urged those considering purchasing performance enhancing products via the internet to think again.

21 Feb 2012

Stimulants do not increase risk of cardiovascular events in youth with ADHD

Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.

9 Feb 2012

Scientists reveal how psychostimulant drugs work to control hyperactivity

It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate - known by the trade names Ritalin, Concerta, and Methylin - and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder.

8 Feb 2012

Increasing health problems from caffeinated energy drinks

A study has shown that there is a sharp rise in the number of people who report heart problems, tremors and chest pains after drinking caffeinated energy drinks. The incidences are particularly common among teenagers. Close to 300 calls were made to NSW's poisons centre regarding adverse reactions to energy drinks between January 2004 and the end of 2010, with more than a third of people attending hospital.

18 Jan 2012

Lightlake intends to develop a treatment for premenstrual syndrome overeating

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.

7 Jan 2012

ADHD drugs not bad for the heart: Study

Drugs widely prescribed for attention disorders like Ritalin, Adderall and other drugs, did not increase the risk of serious heart problems in a major study published Monday. This could assure parents of children on these medications on heart-related safety of the medicines.

12 Dec 2011